Rezolute, Inc. (RZLT) company profile
Close on Nov 18, 2026Market cap $411.07MP/E –Yield –
About Rezolute
Pharmaceutical Preparations, SIC 2834
Rezolute, Inc. is a late-stage rare disease biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with forms of hyperinsulinism. The company's principal clinical asset is ersodetug, an intravenously administered human monoclonal antibody designed to down-modulate insulin receptor activity and normalize blood glucose levels. Its pipeline targets conditions such as congenital hyperinsulinism in pediatric patients and tumor hyperinsulinism caused by neuroendocrine islet cell tumors and non-islet cell tumors. Potential end users and target recipients include pediatric individuals suffering from congenital hyperinsulinism, as well as hospitalized or adult patients with inoperable or metastatic tumors experiencing severe hypoglycemia.
The company operates in the United States and has conducted multinational clinical studies for its therapeutic programs. Rezolute maintains an executive office and headquarters located in Redwood City, California, and employed 58 full-time staff members based entirely in the United States as of June 30, 2026.
Summary of the business section of Rezolute's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rezolute, Inc.
- Founded
- 2010
- Headquarters
- Redwood City, CA
- Address
- 275 Shoreline Drive, Suite 500 94065
- Phone
- (650) 206-4507
- Website
- rezolutebio.com
- Employees
- 58, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- June 30
- Auditor
- GRANT THORNTON LLP, Newport Beach, California
Stock & identifiers
- Ticker
- RZLT
- Former tickers
- ANTB until Feb 14, 2018; FMYY until May 15, 2013
- Exchange
- Nasdaq
- IPO date
- Jan 14, 2013
- Shares outstanding
- 97M, Sep 21, 2026
- Public float
- $203.92M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Oct 13, 2020; 1-for-6 reverse, May 1, 2014
- SEC CIK
- 1509261
- CUSIP
- 76200L309
- ISIN
- US76200L3096
- FIGI
- BBG001XWWHL4
- Share class FIGI
- BBG001XWWJC0
- LEI
- 549300T05L48T72P2G08
- EIN
- 27-3440894
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nevan C. Elam | CEO, Director | 605,497 |
| Daron Evans | CFO | 477,400 |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 79,173 |
| Brian Kenneth Roberts | Chief Medical Officer | 309,351 |
| Wladimir Hogenhuis | Director | 119,675 |
| Philippe Fauchet | Director | 55,500 |
| Nerissa Kreher | Director | 58,576 |
| Gil M. Labrucherie | Director | 109,072 |
| Young-Jin Kim | Director | 8,594,336 |
| Erik Harris | Director | 21,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $5.71M | $4.09M | $2.49M | $263 | – |
| FY2025 | $2.85M | $2.10M | $1.58M | $225 | – |
| FY2024 | $1.19M | $4.96M | $601.01K | $217 | – |
| FY2023 | $973.65K | -$1.96M | $738.86K | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Nevan Charles Elam Chief Executive Officer | $655.00K | $450.91K | $3.22M | $1.36M | $25.81K | $5.71M | +100% |
| Brian Roberts Chief Medical Officer | $512.16K | $226.83K | $1.25M | $526.05K | $50.23K | $2.56M | +79% |
| Daron Evans Chief Financial and Business Officer | $480.00K | $242.67K | $1.09M | $460.30K | $15.38K | $2.29M | +33% |
| Sunil Karnawat Chief Commercial Officer | $415.63K | $237.30K | $488.87K | $1.46M | $25.88K | $2.62M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had 58 full-time employees, of which 40 employees were engaged in research and development and 18 employees were engaged in general and administrative functions.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?